Effect of vasopressin on complications of cardiac surgery

Effects of vasopressin on the improvement of cardiac function in patients with ventricular dysfunction during separation from cardiopulmonary pump

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015010212642N7

Enrollment

100

Registered

2015-01-18

Start date

2015-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac disease. Atherosclerotic heart disease

Interventions

Intervention 1: vasopresin with 0.03 microgr/kg dosage starting 30minute before end of CPB and continue until 1hour after that. Intervention 2: normal saline with 0.03 microgr/kg dosage starting 30min

Prevention

vasopresin with 0.03 microgr/kg dosage starting 30minute before end of CPB and continue until 1hour after that.

normal saline with 0.03 microgr/kg dosage starting 30minute before end of CPB and continue until 1hour after that.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inclusion criteria: CABG surgery; elective surgery; EF=30-50% exclusion criteria: emergency surgery; Concomitant valve surgery and coronary; renal and liver failure before surgery; diabetes melitus; allergy to vasopresin; history of seizure

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood pressure. Timepoint: Before, during and after cardiopulmonary bypass. Method of measurement: mmHg with Using a mercury manometer.;Heart rate. Timepoint: Before, during, and after CPB. Method of measurement: with pulseoxymeter device.	—

Secondary

Measure	Time frame
Blood lactate. Timepoint: Before, during, and after CPB. Method of measurement: in term of mmol/l with using arterial blood analyser device.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026